XML 44 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaboration Agreements, License Agreement and Revenues - Roll-forward of Related Contract Liabilities (Detail)
$ in Thousands
9 Months Ended
Sep. 30, 2022
USD ($)
AstraZeneca Agreements [Member]  
Contract with Customer Liability [Line Items]  
Balance at December 31, 2021 $ (171,516)
Additions (57,846)
Currency Translation and Other 3,051
Recognized as Revenue 50,873
Balance at June 30, 2022 (175,438)
Product Revenue, Net [Member] | Direct Sales [Member] | Contract Liabilities [Member]  
Contract with Customer Liability [Line Items]  
Balance at December 31, 2021 (3,176)
Additions (537)
Deduction 2,754
Currency Translation and Other 226
Balance at June 30, 2022 (733)
Drug Product Revenue [Member]  
Contract with Customer Liability [Line Items]  
Balance at December 31, 2021 (39,036)
Additions (74,635)
Reclassified to Accrued Liability 66,361
Recognized as Revenue 326
Balance at June 30, 2022 (46,984)
Drug Product Revenue [Member] | AstraZeneca Agreements [Member] | U.S. [Member]  
Contract with Customer Liability [Line Items]  
Balance at December 31, 2021 (11,171)
Additions 0
Reclassified to Accrued Liability 11,171
Recognized as Revenue 0
Balance at June 30, 2022 0
Drug Product Revenue [Member] | Astellas Agreement [Member] | Japan [Member]  
Contract with Customer Liability [Line Items]  
Balance at December 31, 2021 (1,974)
Additions (2,226)
Reclassified to Accrued Liability 4,200
Recognized as Revenue 0
Balance at June 30, 2022 0
Drug Product Revenue [Member] | Astellas Agreement [Member] | Europe [Member]  
Contract with Customer Liability [Line Items]  
Balance at December 31, 2021 (25,891)
Additions (72,409)
Reclassified to Accrued Liability 50,990
Recognized as Revenue 326
Balance at June 30, 2022 $ (46,984)